tbuckley/cabot-search huggingface dataset:
A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade®, ICL670) Is Well Tolerated and Reduces Iron Burden.
Authors: E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks
Journal: Blood (2005)
NCCN Task Force Report: Breast Cancer in the Older Woman
Authors: Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, Eric P. Winer
Journal: Journal of the National Comprehensive Cancer Network (2008)

Breast cancer is common in older women, and the segment of the U.S. population aged 65 years and older is growing rapidly. Consequently, awareness is increasing of the need to identify breast cancer treatment recommendations to assure optimal, individualized treatment of older women with breast cancer. However, the development of these recommendations is limited by the heterogeneous nature of this population with respect to functional status, social support, life expectancy, and the presence of comorbidities, and by the underrepresentation of older patients with breast cancer in randomized clinical trials. The NCCN Breast Cancer in the Older Woman Task Force was convened to provide a forum for framing relevant questions on topics that impact older women with early-stage, locally advanced, and metastatic breast cancer. The task force is a multidisciplinary panel of 18 experts in breast cancer representing medical oncology, radiation oncology, surgical oncology, geriatric oncology, geriatrics, plastic surgery, and patient advocacy. All task force members were from NCCN institutions and were identified and invited solely by NCCN. Members were charged with identifying evidence relevant to their specific expertise. During a 2-day meeting, individual members provided didactic presentations; these presentations were followed by extensive discussions during which areas of consensus and controversy were identified on topics such as defining the “older” breast cancer patient; geriatric assessment tools in the oncology setting; attitudes of older patients with breast cancer and their physicians; tumor biology in older versus younger women with breast cancer; implementation of specific interventions in older patients with breast cancer, such as curative surgery, surgical axillary staging, radiation therapy, reconstructive surgery, endocrine therapy, chemotherapy, HER2-directed therapy, and supportive therapies; and areas requiring future studies. ( JNCCN 2008;6[Suppl 4]:S1–S25)
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Authors: Soumitri Barua, Robert Greenwald, Jason Grebely, Gregory J. Dore, Tracy Swan, Lynn E. Taylor
Journal: Annals of Internal Medicine (2015)

The aim of this study was to systematically evaluate state Medicaid policies for the treatment of hepatitis C virus (HCV) infection with sofosbuvir in the United States. Medicaid reimbursement criteria for sofosbuvir were evaluated in all 50 states and the District of Columbia. The authors searched state Medicaid Web sites between 23 June and 7 December 2014 and extracted data in duplicate. Any differences were resolved by consensus. Data were extracted on whether sofosbuvir was covered and the criteria for coverage based on the following categories: liver disease stage, HIV co-infection, prescriber type, and drug or alcohol use. Of the 42 states with known Medicaid reimbursement criteria for sofosbuvir, 74% limit sofosbuvir access to persons with advanced fibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis [METAVIR] fibrosis stage F3) or cirrhosis (F4). One quarter of states require persons co-infected with HCV and HIV to be receiving antiretroviral therapy or to have suppressed HIV RNA levels. Two thirds of states have restrictions based on prescriber type, and 88% include drug or alcohol use in their sofosbuvir eligibility criteria, with 50% requiring a period of abstinence and 64% requiring urine drug screening. Heterogeneity is present in Medicaid reimbursement criteria for sofosbuvir with respect to liver disease staging, HIV co-infection, prescriber type, and drug or alcohol use across the United States. Restrictions do not seem to conform with recommendations from professional organizations, such as the Infectious Diseases Society of America and the American Association for the Study of Liver Diseases. Current restrictions seem to violate federal Medicaid law, which requires states to cover drugs consistent with their U.S. Food and Drug Administration labels.
Asthma contol in Tunisia
Authors: Nadia Keskes Boudawara, Leila Boussoffara, Mona Ben Khalifa, Imen Touil, Mounira Sakka, Jalel Knani
Journal: European Respiratory Journal (2012)

Introduction : Control of asthma is related to recent daily symptoms and exacerbations; it represents the ultimate goal of treatments according to current guidelines. The definition of asthma control was derived from the Global initiative for asthma (GINA): totally controlled or well controlled, or uncontrolled.

In Tunisia, we have no data on the level of asthma control in adult patients.

Aims and objectives : This study was conducted to determine how closely asthma management guidelines are being followed in Tunisia and to identify the factors affecting the control of asthma in our country.

Patients and methods : This study is based on information from 163 adults with asthma in 2010-2011. Sociodemographic data, duration of asthma in years, the severity of asthma based on GINA criteria of severity, etiology and treatment of substance was collected. Regarding control asthma, the questionnaire response of the Asthma Control Test has classified as controlled, well controlled, or uncontrolled.

Results : the mean of age was 49 ± 15years. Asthma was intermittent in 3.1%, persistent mild in 31.3%, persistent moderate in 51.5% and persistent severe in14.1%. Treatment as recommended by GINA was applied in 63% of patients. 67.5% of patients were uncontrolled, 26% were well controlled and 6.5% were totally controlled. Factors of uncontrolled asthma were the advanced age (p <0.001) and low Forced Expiratory Volume in one second (FEV1) (P <0.001).

Conclusion : Despite all efforts through international recommendations and despite the existence of effective therapies against asthma, a significant number of patients with asthma remain uncontrolled in this study. Asthma control in Tunisia is probably as poor as in other areas of the world.
Individualized Patient Education and Coaching to Improve Pain Control Among Cancer Outpatients
Authors: Jennifer Wright Oliver, Richard L. Kravitz, Sherrie H. Kaplan, Frederick J. Meyers
Journal: Journal of Clinical Oncology (2001)

PURPOSE: An estimated 42% of cancer patients suffer from poorly controlled pain, in part because of patient-related barriers to pain control. The objective of this study was to evaluate the effect of an individualized education and coaching intervention on pain outcomes and pain-related knowledge among outpatients with cancer-related pain. PATIENTS AND METHODS: English-speaking cancer patients (18 to 75 years old) with moderate pain over the past 2 weeks were randomly assigned to the experimental (n = 34) or control group (n = 33). Experimental patients received a 20-minute individualized education and coaching session to increase knowledge of pain self-management, to redress personal misconceptions about pain treatment, and to rehearse an individually scripted patient-physician dialog about pain control. The control group received standardized instruction on controlling pain. Data on average pain, functional impairment as a result of pain, pain frequency, and pain-related knowledge were collected at enrollment and 2-week follow-up. RESULTS: At baseline, there were no significant differences between experimental and control groups in terms of average pain, functional impairment as a result of pain, pain frequency, or pain-related knowledge. At follow-up, average pain severity improved significantly more among experimental group patients than among control patients (P = .014). The intervention had no statistically significant impact on functional impairment as a result of pain, pain frequency, or pain-related knowledge. CONCLUSION: Compared with provision of standard educational materials and counseling, a brief individualized education and coaching intervention for outpatients with cancer-related pain was associated with improvement in average pain levels. Larger studies are needed to validate these effects and elucidate their mechanisms.
Demonstration of Immunoglobulin in Tumor and Marginal Tissues of Squamous Cell Carcinomas of the Head and Neck 2
Authors: T. Koneval, E. Applebaum, D. Popovic, L. Gill, G. Sisson, G. W. Wood, B. Anderson
Journal: JNCI Journal of the National Cancer Institute (1977)

Immunofluorescence (IF) techniques on cryostat-cut sections of tumor tissues demonstrated that immunoglobulin was associated with cells of squamous cell carcinomas of the head and neck. The immunoglobulin was found consistently to be of the IgG class; IgM and IgA were detected also but in only one tumor sample each. The C3 component of complement was also in most tumor tissues. The immunoglobulin could be removed from the tissues by being washed with low pH glycine buffer but not with pH 7 buffer, indicating that the immunoglobulin may be in antibody-antigen complexes. All the tissues obtained from the histologically normal margins of the surgical specimens were also positive for the presence of bound immunoglobulin, whereas head and neck epithelial tissues from tumor-free control patients were negative in the IF assays. Preliminary experiments showed that IgG from patients' diluted serum and the IgG fraction isolated from patients' serum would bind to glycine buffer-eluted tumor tissue.
Diagnosis and treatment of Parkinson's disease
Authors: C M Hawkes
Journal: BMJ (1995)

Diagnosis and treatment of Parkinson's diseaseAnosmia is a common finding EDrroR,-Niall Quinn's review on the recognition and differential diagnosis of parkinsonism' omits an important point-namely, that at least 70% of patients with idiopathic Parkinson's disease have a defective or absent sense of smell.23About 90% of patients have rigidity and akinesia, and hence impairment of the sense of smell would be the second commonest feature of this condition, at least equalling tremor in its frequency of occur- rence.About half of patients are aware of this defect, and it is suspected, although not yet proved, that anosmia may precede the onset of the motor aspects ofidiopathic Parkinson's disease.This observation has important clinical consequences.If one suspects a patient to have idio- pathic Parkinson's disease and the result of a simple bedside test of olfaction is normal then the diagnosis should be questioned.In progressive supranuclear palsy (Steele-Richardson syndrome), which may simulate idiopathic Parkinson's disease, olfaction is normal.4Furthermore, provisional information suggests that patients with benign essential tremor also have normal smell identifica- tion scores.'This might not permit the distinction from benign tremulous Parkinson's disease as our limited data suggest that olfaction is normal in this rare variety ofparkinsonism.An ideal test for olfactory identification is the University of Pennsylvania smell identification test.Unfortunately, this is quite expensive, but a preliminary assessment may be made with every- day odours such as chocolate, orange peel, coffee, rose, and vanilla.As long as local nasal disease is excluded an important clinical sign may be documented.
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.
Authors: C R Kusnierz-Glaz, P G Schlegel, R M Wong, J R Schriber, N J Chao, M D Amylon, W W Hu, R S Negrin, Y Lee, K G Blume, G D Long
Journal: Journal of Clinical Oncology (1997)

To determine the effect of age on the outcome of autologous bone marrow transplantation (ABMT) and/or peripheral-blood progenitor-cell (PBPC) transplantation.A retrospective analysis was performed on 500 consecutive patients who ranged in age from 1 to 65 years (median, 40) with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), multiple myeloma (MM), or acute nonlymphoblastic leukemia (AML) who underwent autologous hematopoietic-cell transplant procedures at Stanford University Medical Center.The actuarial 5-year event-free survival (EFS) rate was 44%, the relapse rate 47%, and the regimen-related mortality (RRM) rate 8.6%. Disease status at time of transplantation, categorized as either minimal or advanced disease, was the strongest predictive factor for EFS (relative risk (RR) for advanced-disease group, 1.8; P < .0003) and relapse rate (RR for advanced-disease group, 1.9; P < .0004). Patients with minimal or advanced disease had an EFS rate of 48% and 30% and relapse rates of 43% and 72%, respectively. The EFS rate of patients less than 50 years verus > or = 50 years of age was 46% versus 34% (P = .03). Cox regression analysis showed that age was predictive for EFS (RR for patients 50 to 65 years, 1.4; P = .03). The actuarial RRM rate for these age groups was 7.4% versus 12.7% (P = .07), respectively. Multivariate analysis demonstrated that age (odds ratio [OR] for patients 50 to 65 years, 1.9; P < .05) and period of transplantation (OR for most recent years [1991 to 1995], 0.6; P = .06) were the most predictive factors for RRM.Although age greater than 50 years is associated with an inferior outcome following autologous hematopoietic-cell transplantation, it does not appear to be warranted to limit this potentially curative procedure based solely on age. The upper age limit of high-dose therapy with autologous progenitor-cell and/ or bone marrow support remains to be defined.
An Official ATS Clinical Policy Statement: Congenital Central Hypoventilation Syndrome
Authors: Debra E. Weese-Mayer, Elizabeth M. Berry-Kravis, Isabella Ceccherini, Thomas G. Keens, Darius A. Loghmanee, Ha Trang
Journal: American Journal of Respiratory and Critical Care Medicine (2010)

Section:ChooseTop of pageAbstract <<CONTENTSOVERVIEWMETHODSOBJECTIVESTHE STATEMENTA MODEL FOR TRANSITIONAL ...SUMMARY STATEMENTFUTURE DIRECTIONSReferencesCITING ARTICLES
ARRHYTHMIA RECURRENCE IN ADULT PATIENTS WITH SINGLE VENTRICLE PHYSIOLOGY FOLLOWING SURGICAL FONTAN CONVERSION
Authors: Jamil A. Aboulhosn, Ryan J. Williams, Kalyanam Shivkumar, Mark Plunkett, Rakhi Barkowski, Pamela Miner, Hillel Laks, Brian Reemtsen, Kevin Shannon, John Child
Journal: Journal of the American College of Cardiology (2010)
Immunologic Methods for the Identification of Cell Types. I. Specific Antibodies That Distinguish Between Mammary Gland Epithelial Cells and Fibroblasts2
Authors: Karen Thompson, Roberto L. Ceriani, Donald Wong, S. Abraham
Journal: JNCI Journal of the National Cancer Institute (1976)

Antibodies were produced against intact mouse mammary epithelial cells and cleared fat pad fibroblasts; after appropriate absorption, two specific antibody preparations were obtained. The antimammary epithelial cell preparation did not appear to be strain- or species-specific. The antimammary fibroblast preparation recognized both mammary and fetal fibroblasts. These findings suggested that each cell type possessed distinct immunogenic components. These components were characteristic of each cell type and could be used to identify the respective cells by an immunofluorescence technique. Characterization of the antigenic component of mouse mammary epithelial cells demonstrated that this antigen was released during enzymatic cell dissociation and was regenerated underin vitro culture.
Patient education about topical treatments
Authors: M.J. Cork
Journal: British Journal of Dermatology (2011)

Journal Article Patient education about topical treatments Get access M.J. Cork M.J. Cork Academic Unit of Dermatology Research, Department of Infection & Immunity, The University of Sheffield, Sheffield, U.K. E‐mail: m.j.cork@sheffield.ac.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 6, 1 December 2011, Pages 1159–1160, https://doi.org/10.1111/j.1365-2133.2011.10724.x Published: 01 December 2011
Fibrous cavernous pulmonary tuberculosis (FCT) complicated by spontaneous pneumothorax (SP)
Authors: Kazim Mukhamedov, Avazbek Muzrabekov, Sherali Massavirov, Fazilat Ismailova, Nurali Djurayev
Journal: European Respiratory Journal (2011)

We underwent the treatment of SP clinical course that complicate FCT to 233 patients. Men were 205, women were - 17 at the age 18-72 yr. 121 patients were referred by antituberculous dispensaries, 31 from other TB clinics, 18 from general medical network (GMN), 37 from penitentiary system, 15 went to clinics themselves. Duration of tuberculosis (TB) fluctuated from 1 year to 16 years. MBT were revealed in 90,6% patients. 33 patients were admitted to clinic within 1-7 days with onset of SP process, 190 patients in more late terms (from 15 days to more than 1 month). Before admitting to clinic 134 patients had been made punctures and drainage of pleural cavity (PC). 139 patients were admitted with complicated pleura empyema, 84 - had a mild favorable SP process. The treatment started with puncture and drainage of PC. Polychemotherapy was made in standard regime and by broad-spectrum antibiotics when indicated as well as correction of dysproteinemia and hypovitaminosis, oxygen-soda and ionic condition. Surgically approaches were used just in 5 patients with good effect. Segmental pulmonary resection was performed to 1, pneumectomy-1, bullectomy-1, and pleurectomy-2.  Clinical convalescence was reached in 32, improvement in 86, no changes in 46, and impairment in 3. Lethality was in 25, 1% cases.   Conclusion:  SP problem under FCT is urgent. The search of new ways for more effective diagnostics and treatment to this severe group of patients is needed. At present time, the causes of poor surgical activity are mostly related with large spread and TB process activity, of phthisysurgeons and anesthesiologists being overcareful and lack of qualification as well as good equipment of surgical services.
Lactemia in the evaluation of exercise
Authors: Regina Monteiro, Sérgio Campainha, Ivone Pascoal, Miguel Guimarães, Natália Taveira
Journal: European Respiratory Journal (2013)

Introduction: Chronic respiratory patients tend to reduce physical activity due to dyspnea and muscle mass loss. Respiratory rehabilitation should include exercise training to break the deconditioning cycle.  Aim: Compare serum lactate ([Lac]) with heart rate (HR) and Borg scale (BS) in the evaluation of exercise intensity.  Methods: 21 chronic respiratory patients were submitted to 20 sessions of training on stationary bicycle. Each session included 4 peaks of 3 min with intensity above the anaerobic threshold (determined by cycle ergometer test). HR, peripheral saturation of O2 and 10 point BS were monitored in every training. [Lac] was determined after the first (1st) and last sessions.  Results: Patients had 58 (+/-8,1) years and FEV1 of 48,1 (+/-16,9) %. FEV1 related to the maximum load (MaxL) determined by cycle ergometer test (ρ=0,503; p=0,02).  In the 1st sessions the peak loads ranged from 30 to 80W (52-82% of MaxL); HR from 101 to 160bpm; BS from 0,5 to 9 and [Lac] from 2,1 to 9mmol/l. In the last sessions the peak loads ranged from 35 to 105W (61-122% of MaxL); HR from 103 to 148bpm; BS from 0 to 4 and [Lac] from 3 to 10mmol/l. The load related to the [Lac] both in the 1st (ρ=0,597; p=0,004) as in the last session (ρ=0,604; p=0,004). The association with HR was smaller and only in the 1st session (ρ =0,446; p=0,043). There was no association between the load and BS.  Conclusion: The association of FEV1 and MaxL confirms the functional limitation of the respiratory patients. The relationship between [Lac] and the load performed shows its usefulness in the determination of exercise intensity, better than HR or BS.
Increased heart rate modulation, sympathetic dominance and systemic inflammation in chronic obstructive pulmonary disease
Authors: Devi Jyoti Dash, Sunil Kumar Chhabra, Mansi Gupta, Swapna Ramaswamy, Vishal Bansal, K.K. Deepak
Journal: European Respiratory Journal (2014)

Background.  Cardiac autonomic dysfunction, an independent determinant of adverse outcomes in many diseases, also occurs in Chronic Obstructive Pulmonary Disease (COPD). However, observations have been equivocal, its clinical correlates are poorly defined and association with systemic inflammation unexplored, this study being carried out to address these gaps in knowledge.   Materials and Methods.  Sixty three patients of COPD and 36 controls underwent spirometry, estimation of diffusion capacity, six-minute walk test and measurement of serum interleukin 6 and C-Reactive protein. Cardiac autonomic activity was evaluated by a five-minute heart rate variability (HRV) recording to obtain standard time- and frequency-domain indices.   Results.  HRV indices of overall autonomic modulation, the standard deviation of time intervals between consecutive normal beats (SDNN) and total power were greater in patients with increased levels of several indices of parasympathetic and sympathetic activity. The five-minute averaged heart rate was significantly greater in patients indicating a sympathetic dominance and was inversely correlated with diffusion capacity. Serum interleukin -6 was inversely correlated with pNN50, an index of parasympathetic activity, and positively with LF/HF ratio, that reflects sympathetic:parasympathetic balance. No HRV parameter was associated with physiological measures of severity.   Conclusions . Patients with COPD have increased cardiac autonomic modulation with sympathetic dominance. This is associated with decreased lung diffusion capacity and systemic inflammation.